Carvedilol (¿1-[carbazolyl-(4)-oxy]-3-[2-methoxyphenoxyethyl)amino]-pro panol-(2) ¿) is a novel compound used in clinical practice for the treatment of congestive heart failure, mild to moderate hypertension, and myocardial infarction. Carvedilol was also shown to protect cardiac mitochondria from oxidative stress events. Because mitochondria are the main suppliers of ATP for cardiac muscle wor...

scavenges free radicals of oxygen (Feuerstein et al., 1997). It is used to treat systemic arterial hypertension (Cournot et al., 1992; Lund-Johansen et al., 1992) and congestive heart failure (DasGupta et al., 1991) and is purported to improve exercise capacity (Cleland et al., 1996; Hampton, 1996) and longevity in humans (Bristow et al., 1996). Carvedilol is well absorbed from the gastrointest...

Object To test the clinical usefulness of chronotherapy with a -blocker, evening carvedilol administration was added to first-line antihypertensive therapy in patients with essential hypertension showing a morning blood pressure surge. Methods Patients with hypertension (12 men and 5 women) were treated with first-line antihypertensive drugs for 4 weeks and then underwent 24-hr ambulatory blood...

Objective: To determine whether patients with congestive heart failure on different β adrenoreceptor blocking drugs have similar haemodynamic responses to dobutamine. Design: Single centre, single blind, randomised, two period crossover study comparing carvedilol with metoprolol CR/XL. Patients: Ten patients with stable chronic congestive heart failure (ejection fraction < 40%) on chronic treat...

Lysosomal degradation of ubiquitinated β(2)-adrenergic receptors (β(2)ARs) serves as a major mechanism of long-term desensitization in response to prolonged agonist stimulation. Surprisingly, the βAR antagonist carvedilol also induced ubiquitination and lysosomal trafficking of both endogenously expressed β(2)ARs in vascular smooth muscle cells (VSMCs) and overexpressed Flag-β(2)ARs in HEK-293 ...

OBJECTIVE Chagas' disease has spread throughout Latin America because of the high rate of migration among these countries. Approximately 30% of Chagas' patients will develop cardiomyopathy, and 10% of these will develop severe cardiac damage leading to heart failure. Beta-blockade improves symptoms and survival in heart failure patients; however, its efficacy has not been well established in Ch...

OBJECTIVES The aim of this study, a substudy of the Australia-New Zealand trial of carvedilol in patients with heart failure due to ischemic heart disease, was to determine the effects of this treatment on left ventricular size and function with the use of quantitative two-dimensional (2D) echocardiography. BACKGROUND Beta-adrenergic blocking drugs have been shown to improve left ventricular ...

BACKGROUND The purpose of this study was to examine the effects of carvedilol therapy on autonomic control of the heart and QT-interval dispersion (QTd) among children with idiopathic dilated cardiomyopathy (DCM) whose symptoms were not adequately controlled with standard congestive heart failure therapy. MATERIAL AND METHODS Patients with DCM who were treated with carvedilol were enrolled in...

OBJECTIVES We sought to evaluate the effects of carvedilol on mortality and morbidity in dialysis patients with dilated cardiomyopathy. BACKGROUND Several lines of evidence support the concept that therapy with beta-blocking agents reduces morbidity and mortality in patients with congestive heart failure (HF), but the demonstration of such a survival benefit in dialysis patients with dilated ca...

BACKGROUND Large clinical trials using the betablockers carvedilol, metoprolol, bisoprolol and nebivolol have demonstrated improvement of survival and symptoms in patients with heart failure. Despite the lack of scientific evidence, it is plausible that their beneficial effects are extensible to other betablockers. OBJECTIVE To evaluate the impact of the replacement of carvedilol for proprano...